Strand and Pharmidex to collaborate to produce a new in silico technology for CNS drug discovery
Strand Life Sciences announced that it has entered into a collaboration with Pharmidex. Both companies focus on providing solutions to facilitate the discovery and development of new medicines. Under the collaborative agreement both Strand and Pharmidex will promote each others existing offerings and will jointly develop new software to predict the ability of compounds to cross the blood-brain barrier (BBB). This effectively combines the in silico expertise of Strand with the BBB-focused offering of Pharmidex, which includes in vitro, ex vivo and in vivo methodologies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Celera Diagnostics Identifies Novel Genetic Markers Linked to Increased Risk of Heart Attack - Discoveries Presented at the International Vascular Biology Meeting; Expanded Understanding of Disease Biology Creates Diagnostic and Therapeutic Opportunities
Akela and Nventa announce merger
Novartis gains positive CHMP opinion for Lucentis (ranibizumab) to treat vision loss due to macular edema secondary to RVO
Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Abductor_digiti_minimi_muscle_(foot)
The 5-HT3 Receptor Antagonist Aloxi Launched in Japan
EGene Inc. Announces Its Strategic Full-Service Distribution Alliance with AH Diagnostics of Denmark
Mucosis Appoints Dr. Roberto Grimaldi As Chief Medical Officer
Crucell Announces Excellent Results for Influenza Antibody
Depomed initiates phase II clinical trial for Gabapentin ER in pain indication
